New York, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Factors attributed to the growing CAGR and high demand for the antiviral drugs market are higher incidences of HIV and other life-threatening diseases accompanied with product launches, technological progressions and overall public awareness regarding well-being of human health

According to the current analysis of Reports and Data, the global antiviral drugs market was valued at USD 49.87 billion in 2018 and is expected to reach USD 71.48 billion by year 2026, at a CAGR of 4.6%. Antiviral drugs help to diminish the duration of flu symptoms in otherwise healthy children and adults and may lessen the severity of common flu symptoms. Antiviral drugs are medicines that reduce the intensity of flu viruses to reproduce. Most antivirals are used for specific viral infections, while a broad-spectrum antiviral is effective against a wide range of viruses. Antiviral drugs are suggested for both treatment and prevention of flu. Antiviral drugs work best when consumed within 48 hours of beginning of flu symptoms, but they may still offer benefits when taken later depending upon the nature of the flu. They may also reduce the risk of complications such as ear infections in children, respiratory complications requiring antibiotics, and hospitalization in adults. Viruses use the host's cells to replicate thus, creating a safe and effective antiviral drug is tough.

Rising incidences of viral infection along with increase in public awareness, rise in healthcare expenditure, effective investments on R&D and development of severe and life-threatening diseases is likely to foster the growth of the global antiviral drugs market. Furthermore, Huge target population is provided by increasing frequency of STIs caused by human immunodeficiency virus and human papillomavirus.     

Request free sample of this research report at:

Further key findings from the report suggest

  • Growing incidences of HIV is likely to create higher demand for global antiviral drugs market. According to the statistics estimated by World Health Organization, around 70 million people have been infected with the HIV virus and about 35 million people have died of HIV
  • Complications of influenza, and other illnesses that resemble influenza, may require different treatment and in some cases, urgent medical attention which prescribes antiviral drugs for curation. Influenza viruses can become resistant to specific anti-influenza antiviral drugs, and all of these drugs may have side effects
  • HIV segment in the applications is likely to hold the highest market share during the forecast period due to growing incidences of HIV infections across the globe. HIV held a market share of roughly, 49.1% in the year 2018
  • Asia-Pacific regions registers the fastest growth in the antiviral drugs market with highest CAGR of 5.5%. Rising awareness regarding HIV and initiatives taken by the governments in the region to encourage the treatment of the disease will fuel the market growth in APAC
  • Owing to the introduction of new and solid drugs along with effective R&D practices, hepatitis registered as the fastest growing segment in the applications with highest compounded annual growth rate of 5.3%
  • North America held a market share of 35.1% in the year 2018. High level of R&D in the region makes North America to have chief market share in the market
  • Branded drugs segment dominated the antiviral drugs market with a market share of approximately, 53.2% due to availability of wide range of products along with high prescription rate
  • Key market players in the global antiviral drugs market include, Gilead Sciences, F. Hoffmann-La Roche AG, GlaxoSmithKline, Bristol-Myers-Squibb, AbbVie, Johnson & Johnson, Merck & Co., Aurobindo Pharma, Cipla, and Dr Reddy’s

To identify the key trends in the industry, click on the link below:

Segments covered in the report:

For the purpose of this study, Reports and Data have segmented the Global Antiviral Drugs market on the basis of type, application, mechanism of action and region:                     

Type (Revenue, USD Million; 2016–2026)

  • Branded
  • Generic

Application (Revenue, USD Million; 2016–2026)

  • HIV
  • Hepatitis
  • Herpes Simplex Virus
  • Influenza
  • Others

Mechanism of Action (Revenue, USD Million; 2016–2026)

  • Reverse transcriptase inhibitors
  • Nucleotide polymerase inhibitors
  • Protease inhibitors
  • Others

Order Now:
Regional Outlook (Revenue in USD Million; 2016–2026)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
    • Latin America
  • Brazil

Browse more similar reports on Pharma and Healthcare category by Reports And Data

Cetuximab Market -

Fluorouracil Market -

Palbociclib Market -

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Contact Us:
John Watson
Head of Business Development
Reports And Data | Web:
Direct Line: +1-800-819-3052